Skip to main content
. 2015 Aug 5;16(8):18033–18053. doi: 10.3390/ijms160818033

Table 6.

Treatment recommendations for patients with decompensated liver cirrhosis.

HCV Genotype Therapy
GT 1
  • ●

    Ledipasvir + Sofosbuvir + Ribavirin for 12 weeks. In case of Ribavirin intolerance treatment prolongation up to 24 weeks should be evaluated.

  • ●

    Simeprevir + Sofosbuvir for 12 weeks.
GT 2
  • ●

    Sofosbuvir + Ribavirin for up to 48 weeks.
GT 3
  • ●

    Sofosbuvir + Daclatasvir + Ribavirin for 24 weeks.
GT 4
  • ●

    Ledipasvir + Sofosbuvir + Ribavirin for 24 weeks.
GT 5/6
  • ●

    No data available.

Recommendations for patients with decompensated liver cirrhosis. Since drug approval of the DAA’s vary, health care cost recovery should be evaluated prior to treatment start. Recommendations are given for DAA combinations with most data available at the moment.